KFAS
RVMD icon

Keating Financial Advisory Services’s Revolution Medicines RVMD Stock Holding History

Keating Financial Advisory Services’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.9K Buy
69
+8
+13% +$1.17K ﹤0.01% 1155
2026
Q1 		$5.93K Buy
61
+8
+15% +$808 ﹤0.01% 1355
2025
Q4 		$4.22K Buy
+53
New +$3.48K ﹤0.01% 1336

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Keating Financial Advisory Services's RVMD Position: Q2 2026 in Review

Keating Financial Advisory Services increased its Revolution Medicines (RVMD) stake by 13% in Q2 2026, buying an estimated $1.17K and bringing the position to 69 shares worth $12.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1155.

Keating Financial Advisory Services first reported a position in RVMD in Q4 2025 and has held it in 3 quarters since. 694 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • Keating Financial Advisory Services held 69 shares of Revolution Medicines worth $12.9K as of Q2 2026.
  • Keating Financial Advisory Services bought 8 Revolution Medicines shares in Q2 2026, an estimated $1.17K.
  • Revolution Medicines made up ﹤0.01% of Keating Financial Advisory Services's portfolio in Q2 2026, its #1155 holding.
  • Keating Financial Advisory Services first reported a position in Revolution Medicines in Q4 2025 and has held it in 3 quarters since.
  • 694 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Keating Financial Advisory Services's 13F filing for Q2 2026, filed 11 Aug 2026.